Rossby Financial LCC Takes Position in Humacyte, Inc. (NASDAQ:HUMA)

Rossby Financial LCC bought a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, HoldingsChannel reports. The firm bought 25,000 shares of the company’s stock, valued at approximately $126,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Endowment Wealth Management Inc. increased its stake in Humacyte by 3.6% in the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after acquiring an additional 3,590 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Humacyte by 18.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after purchasing an additional 4,327 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Humacyte by 4.6% in the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after purchasing an additional 5,005 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Humacyte by 25.3% in the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock worth $132,000 after buying an additional 5,293 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Humacyte by 22.0% during the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock worth $198,000 after buying an additional 7,069 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Humacyte

In other news, CFO Dale A. Sander purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, April 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now owns 91,207 shares of the company’s stock, valued at approximately $120,393.24. This trade represents a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 83,993 shares of company stock worth $118,224. Insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

HUMA has been the topic of a number of analyst reports. Benchmark reiterated a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Humacyte in a research report on Wednesday, March 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $13.71.

Humacyte Stock Up 3.4 %

Shares of NASDAQ:HUMA opened at $1.54 on Wednesday. The firm has a market cap of $238.88 million, a P/E ratio of -1.15 and a beta of 1.62. Humacyte, Inc. has a 12 month low of $1.15 and a 12 month high of $9.97. The company’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $4.12.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. As a group, equities analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.